Cytokinetics, Incorporated (NASDAQ:CYTK – Get Free Report) was the target of a large increase in short interest during the month of May. As of May 31st, there was short interest totalling 16,420,000 shares, an increase of 15.7% from the May 15th total of 14,190,000 shares. Based on an average daily volume of 2,290,000 shares, the short-interest ratio is currently 7.2 days. Currently, 14.9% of the company’s shares are short sold.
Insider Activity
In related news, EVP Fady Ibraham Malik sold 32,605 shares of the firm’s stock in a transaction dated Tuesday, April 9th. The stock was sold at an average price of $74.31, for a total transaction of $2,422,877.55. Following the completion of the sale, the executive vice president now directly owns 138,567 shares of the company’s stock, valued at approximately $10,296,913.77. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, EVP Fady Ibraham Malik sold 32,605 shares of Cytokinetics stock in a transaction on Tuesday, April 9th. The stock was sold at an average price of $74.31, for a total value of $2,422,877.55. Following the completion of the transaction, the executive vice president now directly owns 138,567 shares in the company, valued at $10,296,913.77. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director John T. Henderson sold 10,562 shares of the business’s stock in a transaction on Thursday, April 25th. The stock was sold at an average price of $64.54, for a total transaction of $681,671.48. Following the transaction, the director now owns 32,070 shares of the company’s stock, valued at approximately $2,069,797.80. The disclosure for this sale can be found here. Insiders have sold a total of 133,093 shares of company stock valued at $7,892,234 in the last quarter. Insiders own 3.40% of the company’s stock.
Hedge Funds Weigh In On Cytokinetics
Several hedge funds have recently added to or reduced their stakes in the business. First Turn Management LLC acquired a new stake in shares of Cytokinetics in the fourth quarter valued at approximately $67,414,000. Westfield Capital Management Co. LP acquired a new stake in Cytokinetics during the 1st quarter valued at $51,277,000. Norges Bank purchased a new position in Cytokinetics during the fourth quarter worth $60,299,000. Assenagon Asset Management S.A. purchased a new stake in shares of Cytokinetics in the fourth quarter valued at $46,308,000. Finally, Fisher Asset Management LLC acquired a new stake in shares of Cytokinetics during the fourth quarter valued at $44,754,000.
Wall Street Analysts Forecast Growth
View Our Latest Report on CYTK
Cytokinetics Price Performance
CYTK opened at $52.78 on Tuesday. Cytokinetics has a 1-year low of $25.98 and a 1-year high of $110.25. The stock has a market cap of $5.53 billion, a P/E ratio of -9.77 and a beta of 0.75. The stock’s 50 day simple moving average is $60.35 and its 200 day simple moving average is $65.94.
Cytokinetics (NASDAQ:CYTK – Get Free Report) last posted its earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($1.33) EPS for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.17). The business had revenue of $0.84 million during the quarter, compared to the consensus estimate of $0.91 million. During the same quarter last year, the firm posted ($1.38) EPS. The business’s quarterly revenue was down 81.8% compared to the same quarter last year. Research analysts expect that Cytokinetics will post -4.55 EPS for the current fiscal year.
Cytokinetics Company Profile
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.
See Also
- Five stocks we like better than Cytokinetics
- Stock Analyst Ratings and Canadian Analyst Ratings
- Buffett Bails on BYD: What It Means for the Future of EV Stocks
- Best Stocks Under $10.00
- Domino’s vs. Papa John’s: Stock Showdown of Pizza Giants
- The Significance of Brokerage Rankings in Stock Selection
- Williams-Sonoma Makes Stock More Accessible with a Stock Split
Receive News & Ratings for Cytokinetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics and related companies with MarketBeat.com's FREE daily email newsletter.